Abstract
In this age of modern diagnostic procedures and highly developed conservative and surgical therapeutic strategies in oncology, pancreatic carcinoma of ductal origin is still almost invariably an incurable disease [1, 2]. A characteristic tumor biology with regard to growth behavior, metastatic mode, and unspecific symptoms in the initial stage are responsible for this poor prognosis [3–5]. The incurability of pancreatic cancer is duly emphasized by the evaluation of data collected from 15 000 patients. These statistics show that after 5 years, independent of the type of therapy, a total of 60 patients (0.4% with 5-year survival) were still alive [2]. Only about 10%–20% of the patients are able to undergo a potentially curative operation in the form of a partial or total pancreatoduodenectomy [1, 2, 6–9]. The therapeutic dilemma is further characterized by the lack of response to chemo- or radiotherapy [10–15].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Beger HG, Bittner R (1985) Die operative Therapie beim Pankreaskopfkarzinom. Eine chirurgische Standortbestimmung. Z Gastroenterol 23: 240
Gudjonsson B, Livstone EM, Spiro HM (1978) Cancer of pancreas. Cancer 42: 2494
Hermanek P (1984) Pathologie der Pankreastumoren. In: Gebhardt C (ed) Chirurgie des exok- rinen Pankreas. Thieme, Stuttgart, p 192
Kümmerle F, Mangold G, Rückert K (1979) Chirurgie des Pankreas. Internist 20: 399
Moossa AR, Levin B (1981) The diagnosis of “early” pancreatic cancer. Cancer 47: 1688
Beger HG, Bittner R (1986) Das Pankreaskarziom. Springer-Verlag, Berlin Heidelberg New York Tokyo
Knight RW, Scarborough JP, Goss JC (1978) Adenocarcinoma of the pancreas. A 10-year ex-perience. Arch Surg 113: 1401
Malt RA (1983) Treatment of pancreatic cancer. JAMA 250: 1433
Moossa AR (1982) Pancreatic cancer. Approach to diagnosis, selection for surgery and choice of operation. Cancer 50: 2689
Dobelbower RR Jr (1981) Current radiotherapeutic approaches to pancreatic cancer. Cancer 47: 1729
Frey C, Twomey P, Keehn R, Elliot D, Higgens E (1981) Randomized study of 5-FU and CCNU in pancreatic cancer. Cancer 47: 27
Gall FP, Zirngibl H (1984) Chirurgische Therapie der Pankreastumoren. In: Gebhardt C (ed) Chirurgie des exokrinen Pankreas. Thieme, Stuttgart, p 235
Klapdor R, Lehmann U, v Ackeren H, Schreiber HW, Klöppel G, Greten H (1986) Chemotherapy des inoperablen Pankreaskarzioms. In: Beger HG, Bittner R (eds) Das Pankreaskar-ziom. Springer-Verlag, Berlin Heidelberg New York Tokyo
Mallinson CN, Rake MO, Cocking JB, Fox CA, Cwynarski MT, Diffey BL, Jackson GA, Hanley J, Wass VJ (1980) Chemotherapy in pancreatic cancer. Br Med J 281: 1589
Tepper J, Nardi G, Suit H (1976) Carcinoma of the pancreas. Analysis of surgical failure and implications for radiation therapy. Cancer 37: 1519
Bosslet K, Kern HF, Kanzy EJ, Steinsträsser A, Schwarz A, Lüben E, Schorlemmer HU, Sedlaczek HH (1986) A monoclonal antibody with binding and inhibiting activity towards human pancreatic carcinoma cells. Cancer Immunol Immunother 23: 185
Schorlemmer HU, Bosslet K, Kern HF, Sedlaczek HH (1988 in press) A monoclonal antibody with binding and inhibiting activity towards human pancreatic carcinoma cells. Cancer Immunol Immunother
Houghton AN, Mintzer D, Cordon-Cardo C, Welt S, Fliegel B, Vadhan S, Carswell E, Melamed MR, Oettgen HF, Old RJ (1985) Mouse monoclonal IgG3 antibody detecting G D3 ganglioside: A phase I trial in patients with malignant melanoma. Proc Nat Acad Sei USA 82: 1242
Sears HF, Herlyn D, Steplewsky Z, Koprowski H (1985) Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma. Cancer Res 45: 5910
Kübel R, Büchler M, Baczako K, Beger HG (1986) Immunohistochemical analysis of new monoclonal antibodies for pancreatic carcinoma associated antigens. In: Greten H, Klapdor R (eds) Tumor markers. Thieme, Stuttgart, p 76
Montz R, Klapdor R, Rothe B, Heller M (1986) Immunoscintigraphy and radioimmunotherapy patients with pancreatic carcinoma. Nuklearmedizin 25: 239
Kern HF, Bosslet K, Sedlaczek HH, Schorlemmer HU (1986) Monocyte specific functions expressed in cell lines from human pancreatic adenocarcinoma. Dig Dis Sei 31: 1136
Klapdor R, Lander S, Balo M, Montz R (1986) Radioimmunotherapy of xenografts of human pancreatic carcinomas. Nucl Med 25: 235
Karnofsky DA, Abelmann WH, Craver LF, Burdenal JH (1948) The use of the nitrogen mustards in the palliative treatment of carcinoma. Cancer 1: 634
Kübel R, Büchler M, Baczako K, Beger HG (1987) Immunhistochemie beim Pankreaskarziom mit dem monoklonalen Antikörper BW 494. Lang Arch Chir 371: 5–9
Hsu SM, Raine L, Fanger H (1981) The use of avidin-biotin peroxidase complex in immunoperoxidase techniques. Cytochem 29: 577
Sternberger LA (1974) Immunohistochemistry. Prentice-Hall, Englewood Cliffs, NJ
Kübel R, Büchler M, Bosslet K, Beger HG (1987) Antibody dependent cellular cytotoxicity ( ADCC) in patients with gastrointestinal cancer. Cancer Res Clin Oncol 113: 41
Sears HF, Matthys J, Herlyn D, Häyry P, Atkinson B, Ernst C, Steplewski Z, Koprowski H (1982) Phase I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours. Lancet 1: 762
Watts DG (1981) An introduction to nonlinear least squares. In: Endrenyi L (ed) Kinetic data analysis. Raven, New York, pp 1–37
Madry N, Harthus HP (1987) Anwendung von monoklonalen Antikörpern in-vivo: Messung der Maus-Antikörper und der Anti-Maus-Antikörper-Serumspiegel. Lab Med 10: 161
Herlyn D, Koprowsky H (1982) IgG2a monoclonal antibodies inhibit tumor growth through interaction with effector cells. Proc Natl Acad Sci USA 79: 4761
Schulz G, Staffileno LK, Reisfeld RA, Dennert G (1985) Eradication of established human melanoma tumors by antibody directed effector cells. J Exp Med 161: 1315
Schulz G, Bumol TF, Reisfeld RA (1983) Monoclonal antibody directed effector cells selec-tively lyse human melanoma cells in vitro and in vivo. Proc Natl Acad Sci USA 80: 5407
Koprowsky H, Herlyn D, Lübeck M, De Freitas E, Sears H (1984) Human anti-idiotype anti-bodies in cancer patients: is the modulation of the immune response beneficial for the patient? Proc Natl Acad Sei USA 81: 216
Goldstein G, Fuccello AJ, Norman DJ (1986) OKT3 monoclonal antibody plasma levels during therapy and the subsequent development of host antibodies to OKT3. Transplantation 42: 57
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Springer-Verlag Berlin · Heidelberg
About this paper
Cite this paper
Büchler, M. et al. (1989). Immunotherapy of Pancreatic Cancer with Monoclonal Antibody BW 494: Results from a Multicentric Phase I–II Trial. In: Beger, H.G., Büchler, M., Reisfeld, R.A., Schulz, G. (eds) Cancer Therapy. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73721-3_5
Download citation
DOI: https://doi.org/10.1007/978-3-642-73721-3_5
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-73723-7
Online ISBN: 978-3-642-73721-3
eBook Packages: Springer Book Archive